An overview of screening recommendations for HCV and OASAS regulations and the importance of linkage to evaluation and treatment for persons who test positive for HCV. Also covered in this training will be the efficacy of DAA (direct acting antiviral) treatment, including in persons using drugs and alcohol. Harm reduction for patients to discuss risk for acquisition and/or transmission of HCV is also discussed.
This Learning Thursdays presentation fulfills 1 hr of credit toward:
CPP/CPS Section 1 Initial